Welcome to Multibagg AI
Log in to access personalized features
IRIS
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Research powered by GOALZEN CAPITAL SERVICES PRIVATE LIMITED · SEBI Research Analyst INH000013448
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discovery themes featuring this stockBearish
4
Neutral
2
Bullish
8
Bearish
30
Neutral
2
Bullish
14
Bearish
26
Neutral
0
Bullish
6
Bearish
4
Neutral
2
Bullish
8
Bearish
4
Neutral
2
Bullish
8
Bearish
26
Neutral
0
Bullish
6
Bearish
26
Neutral
0
Bullish
6
Bearish
26
Neutral
0
Bullish
6
Investor Presentation
Q2 FY26
Investor Presentation
Q1 FY26
Investor Presentation
Q4 FY25
Smruthi Organics Limited is an India-based manufacturer of Active Pharmaceutical Ingredients (APIs) focused on anti-diabetic, anti-hypertensive and anti-infective therapeutic categories, operating two manufacturing facilities in Solapur with an R&D centre in Hyderabad that develops novel synthetic routes and process improvements for its API portfolio across domestic and ROW markets.
The company posted a strong sequential operational recovery in Q2 FY26 with revenue of Rs. 3,159.52 lakhs and PBT of Rs. 284.65 lakhs, converting H1 FY26 into a net profit of Rs. 96.07 lakhs against prior-year H1 loss, driven by API margins recovering while the Formulation division remains loss-making and small in scale.
Smruthi Organics generated robust operating cash flow of Rs. 1,703.48 lakhs in H1 FY26, used to fund capex of Rs. 550.93 lakhs and to repay borrowings; short-term borrowings fell sharply to Rs. 237.03 lakhs, reflecting meaningful deleveraging and improved liquidity with cash and equivalents rising to Rs. 112.12 lakhs.
The API segment dominates the business, contributing Rs. 5,045.74 lakhs of H1 revenue and most operating profit, while the Formulation segment reported Rs. 21.48 lakhs sales and a loss of Rs. 16.72 lakhs, highlighting concentrated exposure to APIs and the need for either scaling or restructuring the FDF business.
Balance sheet and working capital dynamics show improvement: inventories and trade receivables declined from March levels, total assets reduced to Rs. 9,963.73 lakhs, and management continued investments in PPE and CWIP, suggesting a transition from investment-heavy cycles toward cash generation and balance-sheet consolidation.
Pharmaceuticals & Biotechnology
Pharmaceuticals
153 Cr
Low Risk
20.5
34.8
0.1
2.1
175.30
95.00
Sales CAGR
Profit CAGR
ROE
ROCE
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
31.03 | 166 Cr | 27.10 | 1.16 | 0.00 | 8.93 | 13.60 | 2.10 | ||
154.45 | 161 Cr | -6.48 | 0.92 | 0.00 | -7.27 | -4.85 | -5.85 | ||
133.50 | 153 Cr | 20.46 | 2.08 | 1.12 | 5.54 | 8.84 | 7.16 | ||
9.85 | 144 Cr | 48.10 | 12.18 | 0.00 | 15.34 | 21.17 | 8.18 | ||
176.45 | 143 Cr | 26.61 | 3.81 | 0.00 | 0.00 | 0.00 | 0.00 | ||
29.99 | 142 Cr | 19.73 | 8.01 | 0.00 | 41.95 | 22.81 | 6.97 | ||
129.79 | 142 Cr | 277.98 | 2.13 | 0.00 | 9.95 | 11.89 | 0.99 | ||
| Median: 7 Co. | — | 129.79 | 144 Cr | 26.61 | 2.13 | 0.00 | 8.93 | 11.89 | 2.10 |
Smruthi Organics Ltd (SMRUTHIORG) is currently trading at 135.85 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Smruthi Organics Limited is an India-based manufacturer of Active Pharmaceutical Ingredients (APIs) focused on anti-diabetic, anti-hypertensive and anti-infective therapeutic categories, operating two manufacturing facilities in Solapur with an R&D centre in Hyderabad that develops novel synthetic routes and process improvements for its API portfolio across domestic and ROW markets. The company posted a strong sequential operational recovery in Q2 FY26 with revenue of Rs. 3,159.52 lakhs and PBT of Rs. 284.65 lakhs, converting H1 FY26 into a net profit of Rs. 96.07 lakhs against prior-year H1 loss, driven by API margins recovering while the Formulation division remains loss-making and small in scale. Smruthi Organics generated robust operating cash flow of Rs. 1,703.48 lakhs in H1 FY26, used to fund capex of Rs. 550.93 lakhs and to repay borrowings; short-term borrowings fell sharply to Rs. 237.03 lakhs, reflecting meaningful deleveraging and improved liquidity with cash and equivalents rising to Rs. 112.12 lakhs. The API segment dominates the business, contributing Rs. 5,045.74 lakhs of H1 revenue and most operating profit, while the Formulation segment reported Rs. 21.48 lakhs sales and a loss of Rs. 16.72 lakhs, highlighting concentrated exposure to APIs and the need for either scaling or restructuring the FDF business. Balance sheet and working capital dynamics show improvement: inventories and trade receivables declined from March levels, total assets reduced to Rs. 9,963.73 lakhs, and management continued investments in PPE and CWIP, suggesting a transition from investment-heavy cycles toward cash generation and balance-sheet consolidation.
Over the past 52 weeks, Smruthi Organics Ltd has traded between a low of ₹95.00 and a high of ₹175.30. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Smruthi Organics Ltd has a market capitalization of approximately 152.81. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Smruthi Organics Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 20.46 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 152.81 Cr, Smruthi Organics Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Smruthi Organics Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Smruthi Organics Ltd is 20.46. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
